Multilocus phylogeny and antifungal susceptibility of aspergillus section circumdati from clinical samples and description of A. Pseudosclerotiorum sp. Nov.

J. P.Z. Siqueira, D. A. Sutton, J. Gené, D. García, N. Wiederhold, S. W. Peterson, J. Guarro

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

A multilocus phylogenetic study was carried out to assess species identity of a set of 34 clinical isolates from Aspergillus section Circumdati from the United States and to determine their in vitro antifungal susceptibility against eight antifungal drugs. The genetic markers used were the internal transcribed spacer (ITS) region, and fragments of the beta-Tubulin (BenA), calmodulin (CaM), and RNA polymerase II second largest subunit (RPB2) genes. The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine. The most common species sampled was A. westerdijkiae (29.4%), followed by a novel species, which was described here as A. pseudosclerotiorum (23.5%). Other species identified were A. sclerotiorum (17.6%), A. ochraceus (8.8%), A. subramanianii (8.8%), and A. insulicola and A. ochraceopetaliformis, with two isolates (5.9%) of each. The drugs that showed the most potent activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed the least activity.

Original languageEnglish (US)
Pages (from-to)947-958
Number of pages12
JournalJournal of clinical microbiology
Volume55
Issue number3
DOIs
StatePublished - Mar 2017

Keywords

  • Aspergillus
  • Circumdati section
  • Clinical isolates
  • Molecular identification
  • Phenotypic identification

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Multilocus phylogeny and antifungal susceptibility of aspergillus section circumdati from clinical samples and description of A. Pseudosclerotiorum sp. Nov.'. Together they form a unique fingerprint.

Cite this